BIOATLA INC. - COMMON STOCK

BioAtla Announces Change in Executive Leadership

27 Feb 2023 07:07:17 By Nasdaq GlobeNewswire

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

23 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

10 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

22 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

BioAtla to Participate in the Jefferies London Healthcare Conference

08 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

04 Nov 2022 08:08:20 By Nasdaq GlobeNewswire

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

03 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

27 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

09 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

BioAtla to Participate in the 2022 BTIG Biotechnology Conference

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

02 Aug 2022 07:00:03 By Nasdaq GlobeNewswire

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference

01 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

04 May 2022 15:01:01 By Nasdaq GlobeNewswire

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

08 Apr 2022 07:00:00 By Nasdaq GlobeNewswire